The Food and Drug Administration Aug. 17 issued a safety alert after reviewing the final results from a post-approval study conducted by SynCardia Systems for their Temporary Total Artificial Heart (TAH-t) Companion 2 Driver System. SynCardia’s TAH-t functions as a bridge to a heart transplant in a small population of heart failure patients with severe bi-ventricular failure. The study results indicate a higher mortality rate and higher stroke rate for patients initially supported with the C2 Driver System compared to patients initially supported with the previous generation driver – the Circulatory Support System Console – FDA said. “We recommend that you carefully consider these mortality and stroke results from the TAH-t post-approval study when making treatment decisions, and discuss the risks and benefits of the C2 Driver System with patients,” FDA said in a letter to providers. FDA also encourages providers to report any adverse events or suspected adverse events experienced with the SynCardia TAH-t and Driver Systems.

Related News Articles

Headline
The Centers for Disease Control and Prevention has partnered with Medscape to offer free online training on its recommendations for vaccinating homeless people…
Headline
The HPV vaccine could prevent an estimated 92% of cancers caused by the human papillomavirus in the United States, according to a new study by the Centers for…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response will provide $23 million for Merck to produce…
Headline
The Food and Drug Administration yesterday approved a new antibiotic to treat adults with community-acquired bacterial pneumonia.
Headline
The number of U.S. hospitals with an antibiotic stewardship program that meets all core elements recommended by the Centers for Disease Control and Prevention…
Headline
The Centers for Medicare…